News

April 23, 2021

Valam established the ENT-Office LaserExperts (E-OLE) forum, a virtual, monthly symposium.

The founders of E-OLE composed by well-known worldwide experts, will discuss, teach and promote the use of diode lasers with innovative new accessories that facilitate in-office / ambulatory procedures in Otolaryngology.

February 12, 2021

Valam established a Eustachian Tube Study Group (ETSG).The ETSG members will meet virtually, monthly to explore new therapeutic opportunities.

Founding members of the group are well known experts in the field of ET with decades of experience.

October 31, 2020

October 31, 2020 Valam expands its Board of Directors with a prominent healthcare and medical device senior executive.

David Damm

September 7, 2020

Valam clinical team presented the experience with Blue Laser at a prestigious international meeting, virtually attended by over thousand specialists.

“The Blue Laser – An Ideal Wavelength in Rhinology”

May 1, 2020

The results of a landmark clinical study “Laser ablation of posterior nasal nerves forrhinitis”, sponsored by Valam that was presented in two international meetings was published in a prestigious journal.

“Laser ablation of posterior nasal nerves for rhinitis” https://pubmed.ncbi.nlm.nih.gov/31948695/

April 24, 2020

Maskaion Corp, Valam subsidiary, a Delaware company was established in order to explore respiratory protection opportunity using copper impregnated filters.

www.maskaion.com

March 13, 2020

The clinical study results of Valam biofilm disruption technology for oral malodor in collaboration with Biolase, Inc., is now published.

“Laser tongue debridement for oral malodor-A novel approach to halitosis” https://pubmed.ncbi.nlm.nih.gov/33045536/

January 13, 2020

Valam started to collaborate with IPG Medical and conduct R&D with Alta Blue laser.

Valam to explore ENT surgical applications and study the potential opportunity with this unique wavelength.

December 16, 2019

Valam acquired the assets of BioLx Inc.

Valam has recently acquired the assets of the company BioLx, Inc., a start up with innovative “Respiratory Protection” proprietary technology, including unique face masks and nasal filters. BioLx holds three (3) US patent applications.

Sept. 15, 2019

American Academy of Otolaryngology – September 15-18, 2019

Valam announced today that it will exhibit in the upcoming annual meeting of the American Academy of Otolaryngology (Booth no. 1434), that will take place on September 15 – 18, 2019, in New Orleans, LA.

August 27, 2019

Zelegent Acquires Valam’s MISH Technology Platform, Extending Product Pipeline into Obstructive Sleep Apnea Therapeutics

https://tinyurl.com/y6ggp6hf

July 31, 2018

Valam signed a cross licensing agreement with an undisclosed party for its intellectual property for Laser Removal of Biofilm (Halitosis)

August 2016

Valam, Sinus surgery methods receives U.S. Patent

9,402,686.  Dual access sinus surgery methods

July 1, 2016

Ron Hadani joined Valam as President and CEO.

Valam Corp. today reported that Ron Hadani has been appointed President and Chief Executive Officer and will be leading the company as it enters its commercialization phase and prepares to change its business charter.

May 2014

Valam, Chronic Sinusitis treatment methods receives U.S. Patent

8,721,696 Selective treatments for chronic rhinosinusitis

March 2014

Valam’s, Two step biofilm treatment system receives U.S. Patent

8,679,103 Two step mammalian biofilm treatment processes and systems

February 2012

Valam, Optical therapy and devices receives U.S. Patent

8,109,981 Optical therapies and devices